Please assess the completion status of the following clinical trial:

Trial Title: Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* Currently on ART consisting of at least 3 antiretroviral drugs for at least 12 months prior to study entry and stable (no change in dose) on treatment for at least 3 months prior to study entry~* CD4 count of 100 cells/mm3 or more within 42 days of study entry~* Viral load of 50,000 copies/ml or less within 42 days of study entry~* Willing to use acceptable forms of contraception~* Participants with a Category C AIDS-defining illness during the 12 months prior to study entry may be eligible as long as their CD4 count is 200 cells/mm3 or more at screening. Participants with Kaposi's sarcoma may also be eligible for this study.~Exclusion Criteria:~* Lymphadenopathy greater than 2.0 cm~* Known allergy or sensitivity to study drug or its formulations~* Current drug or alcohol abuse~* Serious illness or hospitalization that, in the opinion of the site investigator, may interfere with the study results~* Prior use of any interleukins~* Systemic cancer chemotherapy, systemic investigational agents, or immunomodulators (e.g., growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interferons) within 90 days prior to study entry~* Heparin within 96 hours prior to study entry, or anticipating the need for heparin within 96 hours after the study injection~* History of cancer (except basal carcinoma of the skin or Kaposi's sarcoma)~* Enlargement of spleen~* History of hypercoagulability (deep vein thrombosis or pulmonary embolism)~* History of seizure disorder~* History of extensive psoriasis, Crohn's disease, uveitis, or other autoimmune disease having induced severe complications~* Significant psychiatric, cardiac, pulmonary, thyroid, renal, or neurological disease requiring therapy~* Positive hepatitis B surface antigen or positive hepatitis C antibody at screening~* Plan to start new ART within 8 weeks after study entry~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).